Bashar Haruna Gulumbe

Dr. Bashar Haruna Gulumbe

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2022 in Biological Procedures Online
Verified
Journal Article
Open access
PDF file
BGBashar Haruna Gulumbe
Bashar Haruna Gulumbe
UHUsman Abubakar Haruna
Usman Abubakar Haruna
JAJoseph Almazan
Joseph Almazan
IIIbrahim Haruna Ibrahim
Ibrahim Haruna Ibrahim
AFAbdullahi Adamu Faggo
Abdullahi Adamu Faggo
ABAbbas Yusuf Bazata
Abbas Yusuf Bazata
The emergence of antibiotic-resistant pathogens has threatened not only our ability to deal with common infectious diseases but also the management of life-threatening complications. Antimicrobial resistance (AMR) remains a significant threat in both industrialized and developing countries alike. In Africa, though, poor clinical care, indiscriminate antibiotic use, lack of robust AMR surveillance programs, lack of proper regulations and the burden of communicable diseases are factors aggravating the problem of AMR. In order to effectively address the challenge of AMR, antimicrobial stewardship programs, solid AMR surveillance systems to monitor the trend of resistance, as well as robust, affordable and rapid diagnostic tools which generate data that informs decision-making, have been demonstrated to be effective. However, we have identified a significant knowledge gap in the area of the application of fast and affordable diagnostic tools, surveillance, and stewardship programs in Africa. Therefore, we set out to provide up-to-date information in these areas. We discussed available hospital-based stewardship initiatives in addition to the role of governmental and non-governmental organizations. Finally, we have reviewed the application of various phenotypic and molecular AMR detection tools in both research and routine laboratory settings in Africa, deployment challenges and the efficiency of these methods.

23 May 2018 in Medical Sciences
Verified
Journal Article
Open access
PDF file
OAOlumide Ajibola
Olumide Ajibola
BGBashar Haruna Gulumbe
Bashar Haruna Gulumbe
AEAnthonius Eze
Anthonius Eze
EOEmmanuel Obishakin
Emmanuel Obishakin
Schistosomiasis is a debilitating disease affecting over 200 million people, with the highest burden of morbidity and mortality in African countries. Despite its huge impact on the health and socio-economic burden of the society, it remains a neglected tropical disease, with limited attention from governments and stakeholders in healthcare. One of the critical areas that is hugely under-developed is the development of accurate diagnostics for both intestinal and urogenital schistosomiasis. Diagnosis of schistosomiasis is important for the detection and treatment of disease in endemic and non-endemic settings. A conclusive detection method is also an indispensable part of treatment, both in the clinic and during mass drug administration (MDA), for the monitoring efficacy of treatment. Here, we review the available diagnostic methods and discuss the challenges encountered in diagnosis in resource limited settings. We also present the available diagnostics and cost implications for deployment in resource limited settings. Lastly, we emphasize the need for more funding directed towards the development of affordable diagnostic tools that is affordable for endemic countries as we work towards the elimination of the disease.

23 June 2025 in Biochemistry and Biophysics Reports
Verified
Journal Article
Open access
EAEsther Ugo Alum
Esther Ugo Alum
BGBashar Haruna Gulumbe
Bashar Haruna Gulumbe
SISylvester Chibueze Izah
Sylvester Chibueze Izah
DUDaniel Ejim Uti
Daniel Ejim Uti
PAPatrick Maduabuchi Aja
Patrick Maduabuchi Aja
COChristian Emeka Offor
Christian Emeka Offor
The global rise of antibiotic resistance (AR) presents a critical threat to public health, prompting the search for innovative antimicrobial strategies. Quorum sensing (QS), a bacterial communication system that governs virulence, biofilm formation, and resistance, has emerged as a compelling non-lethal therapeutic target. This review explores the potential of natural product-based quorum sensing inhibitors (QSIs) derived from plants, microbes, and marine organisms. These compounds disrupt QS pathways through various mechanisms, including inhibition of signal synthesis, receptor antagonism, enzymatic degradation of signaling molecules, and suppression of QS-regulated gene expression. Particular emphasis is placed on the molecular targets and synergistic potential of natural QSIs when combined with conventional antibiotics to enhance efficacy and curb resistance development. This narrative review explores the diverse sources of natural QSIs, including plant-derived phytochemicals, microbial secondary metabolites, and marine bioactive compounds. In this study, a thorough literature search was conducted using databases such as PubMed, Scopus, Web of Science, and Google Scholar. Studies selected were those published between 2013 and 2025 in peer-reviewed journals. The manuscript also examines translational challenges such as poor bioavailability, bacterial adaptability, and regulatory barriers, alongside innovative strategies including nanoparticle-based delivery and combination therapies. Finally, clinical and industrial applications of QSIs are discussed, reinforcing their promise as sustainable tools for combating resistant infections and biofilm-associated diseases. This review underscores QS inhibition as a transformative approach in the ongoing battle against antibiotic resistance.

27 April 2024 in AI & SOCIETY
Verified
Journal Article
Closed access
PDF file
BGBashar Haruna Gulumbe
Bashar Haruna Gulumbe
SAShuaibu Muhammad Audu
Shuaibu Muhammad Audu
AHAbubakar Muhammad Hashim
Abubakar Muhammad Hashim

25 April 2018 in Medicina
Verified
Journal Article
Open access
PDF file
OAOlumide Ajibola
Olumide Ajibola
MBMari Mshelia Bata
Mari Mshelia Bata
BGBashar Haruna Gulumbe
Bashar Haruna Gulumbe
AEAnthonius Eze
Anthonius Eze
Typhoid fever causes significant morbidity and mortality in developing countries, with inaccurate estimates in some countries affected, especially those situated in Sub-Saharan Africa. Disease burden assessment is limited by lack of a high degree of sensitivity and specificity by many current rapid diagnostic tests. Some of the new technologies, such as PCR and proteomics, may also be useful but are difficult for low-resource settings to apply as point-of-care diagnostics. Weak laboratory surveillance systems may also contribute to the spread of multidrug resistant Salmonella serovar Typhi across endemic areas. In addition, most typhoid-endemic countries employ serological tests that have low sensitivity and specificity making diagnosis unreliable. Here we review currently available typhoid fever diagnostics, and advances in serodiagnosis of S. Typhi.

30 January 2025 in Therapeutic Advances in Infectious Disease
Verified
Journal Article
Open access
ASAraj Naveed Siddiqui
Araj Naveed Siddiqui
IMImshaal Musharaf
Imshaal Musharaf
BGBashar Haruna Gulumbe
Bashar Haruna Gulumbe
The emergence of the COVID-19 JN.1 variant has raised global health concerns as it gains prevalence in several regions worldwide. First identified in August 2023, JN.1 evolved from the Omicron lineage’s BA.2.86 subvariant. Patients infected with JN.1 commonly exhibit symptoms such as sore throat, fever, dry cough, nausea, and vomiting. While the World Health Organization has labeled JN.1 a Variant of Interest, it currently presents a low global health risk. However, its increased transmissibility, particularly in cold, dry climates, is concerning. This review provides a comprehensive overview of JN.1’s biological characteristics, epidemiology, transmissibility, immune evasion, and the efficacy of existing antiviral treatments and vaccination strategies. A literature search across key databases targeted studies from January 2023 to August 2024, emphasizing recent insights into JN.1’s spread and clinical impact. Findings reveal that JN.1 exhibits higher infectivity and immune evasion than previous variants, largely due to the L4555 mutation. From November 2023 to March 2024, JN.1 showed an increasing trend in transmission. Previously approved antivirals, including Paxlovid, Veklury, and Lagevrio, demonstrate effectiveness against JN.1, and current vaccines still protect against severe illness from this variant. However, vaccination rates remain low. Monitoring efforts include genomic assessments, wastewater surveillance, and digital tracking to contain the variant’s spread. It is essential to encourage the public to maintain vaccination and preventive measures to reduce JN.1’s impact. Continued research is critical for understanding and managing the evolving landscape of COVID-19 and its emerging variants.